Gibson Dunn Advises Shattuck Labs on Private Placement of Up to Approximately $103 Million
Firm News | August 5, 2025
Gibson Dunn is representing Shattuck Labs, Inc. in connection with a private placement of securities expected to generate aggregate gross proceeds of up to approximately $103 million to a syndicate of healthcare investors led by OrbiMed, including a large, healthcare-dedicated fund, Coastlands Capital, Prosight Capital, Adage Capital, Redmile Group, and NextBio Capital.
Shattuck Labs, Inc. is a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor superfamily receptors for the treatment of patients with inflammatory and immune-related diseases. Shattuck has offices in both Austin, Texas and Durham, North Carolina.
Gibson Dunn regularly advises life sciences companies and healthcare investors on private placements and capital markets transactions in the biotechnology sector.
The Gibson Dunn team included Ryan Murr, Branden Berns, Melanie Neary, Candice Johnson, Jasmine Vitug, and Anika Gidwani.